Exelixis reported 18.02 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
Amgen 18.07 1.77 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
Bayer 4.14 0.74 Jun/2026
BioMarin Pharmaceutical 21.07 5.79 Jun/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Eisai 26.55 9.06 Jun/2026
Eli Lilly 32.9 7.37 Jun/2026
Exelixis 18.02 4.11 Jun/2026
Genmab 16.04 1.05 Jun/2026
Glaxosmithkline 15.09 3.43 Mar/2026
Incyte 14.45 0.9 Jun/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Merck 32.26 15.74 Jun/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 22.41 2.24 Jun/2026
Pfizer 11.48 2.16 Jun/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Sanofi 20.87 5.12 Mar/2026
Takeda 24.4 22.12 Jun/2026
Xencor 29.92 3.22 Sep/2022